ShockWave Medical (NASDAQ:SWAV – Get Rating) and Artivion (NYSE:AORT – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.
Institutional and Insider Ownership
89.1% of ShockWave Medical shares are owned by institutional investors. Comparatively, 81.0% of Artivion shares are owned by institutional investors. 3.9% of ShockWave Medical shares are owned by company insiders. Comparatively, 5.6% of Artivion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Get ShockWave Medical alerts:Profitability
This table compares ShockWave Medical and Artivion's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ShockWave Medical | 15.11% | 21.25% | 15.33% |
| Artivion | -5.55% | 3.42% | 1.29% |
Analyst Recommendations
This is a summary of current ratings and recommmendations for ShockWave Medical and Artivion, as reported by MarketBeat.com.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ShockWave Medical | 0 | 1 | 6 | 0 | 2.86 |
| Artivion | 0 | 1 | 3 | 0 | 2.75 |
ShockWave Medical presently has a consensus price target of $248.17, indicating a potential downside of 14.17%. Artivion has a consensus price target of $28.25, indicating a potential upside of 24.34%. Given Artivion's higher probable upside, analysts clearly believe Artivion is more favorable than ShockWave Medical.
Earnings & Valuation
This table compares ShockWave Medical and Artivion's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ShockWave Medical | $237.15 million | 43.63 | -$9.14 million | $1.46 | 198.04 |
| Artivion | $298.84 million | 3.07 | -$14.83 million | ($0.44) | -51.64 |
ShockWave Medical has higher earnings, but lower revenue than Artivion. Artivion is trading at a lower price-to-earnings ratio than ShockWave Medical, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
ShockWave Medical has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Artivion has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Summary
ShockWave Medical beats Artivion on 10 of the 14 factors compared between the two stocks.
About ShockWave Medical
(Get Rating)
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
About Artivion
(Get Rating)
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.